Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Successful Postpartum CAR T-cell Salvage Therapy for Primary Mediastinal Large B-cell Lymphoma with Residual Disease after R-CHOP During Pregnancy.

Internal medicine (Tokyo, Japan)·2026
Same author

Worst Histology-Based Risk Stratification for Lymph Node Metastasis in Patients With T1b Colorectal Cancer: A Retrospective Pathology-based Study.

DEN open·2026
Same author

[Clinical outcomes of idecabtagene vicleucel therapy for relapsed/refractory multiple myeloma: a single-center retrospective analysis].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same author

Sustaining microglial reparative function enhances stroke recovery.

Nature·2026
Same author

Combined administration of interleukin-2 and 18 with anti-PD-L1 antibody induces CCL5-positive CD8 T cells to suppress liver tumors.

PNAS nexus·2026
Same author

Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.

Blood advances·2026
Same journal

Allogeneic hematopoietic cell transplantation with reduced-toxicity conditioning for X-linked hyper-IgM syndrome.

International journal of hematology·2026
Same journal

Incidence, etiology, and predictors of early mortality after induction chemotherapy for aml in a middle-income country.

International journal of hematology·2026
Same journal

Modified short-course fludarabine-based conditioning regimen for salvage cord blood transplantation after graft failure.

International journal of hematology·2026
Same journal

Cytarabine-based induction and oral maintenance therapy for a single system with single-site Langerhans cell histiocytosis.

International journal of hematology·2026
Same journal

Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis.

International journal of hematology·2026
Same journal

Correction to: Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.

International journal of hematology·2026
See all related articles

Related Experiment Video

Updated: Jan 6, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.0K

Genetic prognostic markers in LymphGen-unclassifiable diffuse large B cell lymphoma.

Yusuke Kanemasa1,2,3, Daichi Sadato4,5, Maya Isogai4,5

  • 1Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. yuusuke_kanemasa@tmhp.jp.

International Journal of Hematology
|September 12, 2025
PubMed
Summary
This summary is machine-generated.

Researchers identified new genetic markers, CDKN2A and PIM1, for diffuse large B cell lymphoma (DLBCL) that is unclassifiable by current methods. This improves risk assessment for patients with this challenging non-Hodgkin lymphoma subtype.

Keywords:
Diffuse large B cell lymphomaGenetic subtypeGenomic alterationsMolecular classificationPrognostic scoring model

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.2K

Related Experiment Videos

Last Updated: Jan 6, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.0K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.2K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, with varied treatment outcomes.
  • Existing genetic subtyping methods like LymphGen leave a subset of DLBCL cases unclassifiable, posing challenges for prognosis.
  • Identifying specific markers for these unclassifiable DLBCL cases is crucial for improving patient risk stratification.

Purpose of the Study:

  • To identify novel prognostic genetic markers for LymphGen-unclassifiable DLBCL.
  • To develop an improved risk assessment model for this specific DLBCL subgroup.

Main Methods:

  • Utilized a discovery cohort from the National Cancer Institute to identify genetic alterations.
  • Validated findings in a separate cohort from Komagome Hospital, Tokyo.
  • Integrated identified genetic markers with the International Prognostic Index (IPI) for risk assessment.

Main Results:

  • Identified significant associations between genetic alterations in CDKN2A and PIM1 and overall survival in LymphGen-unclassifiable DLBCL.
  • Developed a model that, combined with IPI, accurately identified high-risk patients within the high-risk IPI group.
  • Observed a notable difference in 2-year overall survival (38% vs. 72%) between high-risk and lower-risk patients identified by the model.

Conclusions:

  • CDKN2A and PIM1 alterations are prognostic markers for LymphGen-unclassifiable DLBCL.
  • The developed model enhances prognostic accuracy for DLBCL patients lacking distinct genetic features.
  • This research paves the way for more targeted therapies and improved understanding of unclassifiable DLBCL.